Tadalafil zeichnet sich durch eine außergewöhnlich lange Halbwertszeit im Vergleich zu anderen PDE5-Inhibitoren aus. Diese pharmakokinetische Eigenschaft führt zu einer verlängerten Exposition des Wirkstoffs im Organismus. Die Eliminationsrate hängt von der hepatischen Aktivität des CYP3A4-Enzyms ab. Lipophile Eigenschaften unterstützen eine weite Verteilung in unterschiedlichen Geweben. Eine ausgeprägte Stabilität gegenüber Nahrungsaufnahme macht den Stoff besonders konstant in seiner Wirkung. Unter generischen Präparaten wird cialis online häufig mit einem vergleichbaren pharmakologischen Profil beschrieben.

Warfarin loading

Challenges in Haemostasis & thrombosis
British Society for Haemostasis & Thrombosis
7th October 2010
British Library, London
Registration form available at http://www.bsht.org.uk/ or from Conference Organiser,
Jean Machin, at mach263@msn.com
08.30 - 09.20
REGISTRATION, EXHIBITION & coffee & tea
09.20 - 09.30
Welcome & BSHT update
Dr Trevor Baglin
Chairpersons Dr Jim Crawley & Dr Sue Pavord
09.30- 10.00
Hospital-acquired thrombosis
Dr Ander Cohen
- what is the extent of the problem? -is the risk overestimated? - where do we want to get to and how do we get there? 10.00 - 10.30
Understanding flow based haemostasis: the VWF and ADAMTS13 axis
Professor David Lane
- how does ADAMTS13 function as a protease? - what do VWF and ADAMTS13 like about each other? 10.30 - 10.50
NIHR Comprehensive Clinical Research Network
Dr Peter Collins
10.50 -11.20
EXHIBITION & coffee & tea
11.20 - 12.00
Von Willebrands Disease
Dr David Keeling & Dr Anne Goodeve
- is it necessary to classify type 2 VWD? - is a formalised bleeding score useful? 2) Unravelling the genotype-phenotype relationship of Von Willebrand Disease - what have we learnt from genotyping studies? - how should we think about the VWD subtypes from a genetic perspective? - what are we likely to learn in the future? 12.00 - 12.40
Haemophilia A & B
Dr Peter Collins
- what should we do for adults with established inhibitors? 12.40 - 14.00
EXHIBITION, lunch and AGM (12.40 to 13.10)
Chairpersons Dr Paul Harrison & Dr Henry Watson
14.00 - 14.45
Platelet function for the 'non-platelet specialist'
Professor Hans Deckmyn
14.45 - 15.30
Thrombin Generation: what have we learnt so far?
Professor Coen Hemker
15.30 - 16.00
EXHIBITION & coffee & tea
16.00 - 16.30
PROPOSAL AND ROUND TABLE DISCUSSION: A plasma free blood
transfusion service: should all plasma be replaced with factor
concentrates?
- introduction - Trevor Baglin
- the national comparative audit Shubha Allard
- what effect does FFP administration have on clotting tests? Dora Foukanelli
- is the coagulopathy of critical illness a bleeding disorder? Trevor Baglin
Round table discussion with invited experts 16.30- 16.55
Treating acquired coagulopathy with antifibrinolytics: aprotonin and
tranexamic acid
Professor Beverley Hunt
- when should tranexamic acid be prescribed? 16.55 - 17.00
Conclusions and close of meeting
Dr Trevor Baglin
17.00 – 18.00 Drinks reception

Source: http://b-s-h.org.uk/documents/2010728165855Challenges_meeting_London_2010.pdf